{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T06:06:47Z","timestamp":1788934007265,"version":"build-2803163510"},"reference-count":42,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202983"],"award-info":[{"award-number":["82202983"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005089","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L252079"],"award-info":[{"award-number":["L252079"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ann Clin Transl Neurol"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The clinical relevance of MGMT promoter methylation in IDH\u2010mutant gliomas remains controversial in the era of molecular classification. We aimed to systematically evaluate its clinical relevance by integrating quantitative assessment, cutoff exploration, and adjustment for clinical confounding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 558 patients with WHO grade 2\u20133 IDH\u2010mutant gliomas were retrospectively analyzed. MGMT promoter methylation was quantified by pyrosequencing. Survival outcomes were assessed using Kaplan\u2013Meier analysis and multivariable Cox regression. Multiple cutoff thresholds were examined, and PSM was applied to balance baseline characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Quantitative methylation stratification demonstrated significantly shorter PFS and OS in unmethylated tumors compared with methylated tumors. However, no clear stepwise association between increasing methylation levels and survival was observed. Across cutoff thresholds (9%\u201325%), MGMT promoter methylation was consistently associated with improved PFS, whereas its association with OS varied and diminished at higher cutoffs. In the unmatched cohort, MGMT promoter methylation was significantly associated with prolonged PFS (HR\u2009=\u20090.53, 95% CI: 0.33\u20130.85,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009) and OS (HR\u2009=\u20090.39, 95% CI: 0.21\u20130.75,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005). Following PSM, the direction and magnitude of these associations remained comparable (PFS: HR\u2009=\u20090.47, 95% CI: 0.23\u20130.98,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.044; OS: HR\u2009=\u20090.35, 95% CI: 0.12\u20131.05,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.06), although statistical significance was less consistent.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MGMT promoter methylation is associated with favorable clinical outcomes in IDH\u2010mutant gliomas. Its prognostic significance appears to be influenced by treatment context, methodological factors, and cohort characteristics. These findings support a context\u2010dependent interpretation of MGMT methylation and highlight the need for standardized analytical approaches in future studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acn3.70528","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:29:44Z","timestamp":1788931784000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Impact of\n                    <scp>MGMT<\/scp>\n                    Promoter Methylation in\n                    <scp>IDH<\/scp>\n                    \u2010Mutant Gliomas: Influence of Threshold Selection and Clinical Confounding"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8114-9741","authenticated-orcid":false,"given":"Haihui","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Peking University Third Hospital Peking University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linxi","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Peking University Third Hospital Peking University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Peking University Third Hospital Peking University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Peking University Third Hospital Peking University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghui","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Beijing Tiantan Hospital Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Peking University Third Hospital Peking University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Beijing Tiantan Hospital Capital Medical University  Beijing China"},{"name":"National Clinical Research Center for Neurological Diseases, Center of Brain Tumor Beijing Institute for Brain Disorders and Beijing Key Laboratory of Brain Tumor  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Beijing Tiantan Hospital Capital Medical University  Beijing China"},{"name":"National Clinical Research Center for Neurological Diseases, Center of Brain Tumor Beijing Institute for Brain Disorders and Beijing Key Laboratory of Brain Tumor  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"7","key":"e_1_2_13_2_1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nrneurol.2014.100","article-title":"MGMT Testing\u2013The Challenges for Biomarker\u2010Based Glioma Treatment","volume":"10","author":"Wick W.","year":"2014","journal-title":"Nature Reviews. Neurology"},{"issue":"10","key":"e_1_2_13_3_1","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma","volume":"352","author":"Hegi M. E.","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"e_1_2_13_4_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrneurol.2009.197","article-title":"MGMT Promoter Methylation in Malignant Gliomas: Ready for Personalized Medicine?","volume":"6","author":"Weller M.","year":"2010","journal-title":"Nature Reviews. Neurology"},{"issue":"8","key":"e_1_2_13_5_1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: A Summary","volume":"23","author":"Louis D. N.","year":"2021","journal-title":"Neuro\u2010Oncology"},{"issue":"1","key":"e_1_2_13_6_1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11060-022-03955-3","article-title":"Prognostic and Predictive Impact of MGMT Promoter Methylation Status in High Risk Grade II Glioma","volume":"157","author":"Haque W.","year":"2022","journal-title":"Journal of Neuro\u2010Oncology"},{"key":"e_1_2_13_7_1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jocn.2020.12.028","article-title":"Prognostic and Predictive Impact of MGMT Promoter Methylation in Grade 3 Gliomas","volume":"85","author":"Haque W.","year":"2021","journal-title":"Journal of Clinical Neuroscience"},{"issue":"1","key":"e_1_2_13_8_1","doi-asserted-by":"crossref","first-page":"272","DOI":"10.20892\/j.issn.2095-3941.2020.0179","article-title":"Predictive Value of MGMT Promoter Methylation on the Survival of TMZ Treated IDH\u2010Mutant Glioblastoma","volume":"18","author":"Chai R.","year":"2021","journal-title":"Cancer Biology & Medicine"},{"key":"e_1_2_13_9_1","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/neuonc\/noaf287","article-title":"Prognostic Significance of MGMT Promoter Methylation Status in IDH\u2010Mutant Glioma","volume":"28","author":"Youssef G.","year":"2025","journal-title":"Neuro\u2010Oncology"},{"key":"e_1_2_13_10_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2026.150205","article-title":"Impact of IDH Mutation and MGMT Methylation as Independent Prognostic Markers in Uniformly Treated High Grade Glioma Patients: A Real\u2010World Evidence in the Indian Population","volume":"1877","author":"Kumar A.","year":"2026","journal-title":"Brain Research"},{"issue":"3","key":"e_1_2_13_11_1","article-title":"Prognostic Value of Test(s) for O6\u2010Methylguanine\u2010DNA Methyltransferase (MGMT) Promoter Methylation for Predicting Overall Survival in People With Glioblastoma Treated With Temozolomide","volume":"3","author":"McAleenan A.","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"17","key":"e_1_2_13_12_1","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1002\/cncr.27392","article-title":"Comparative Assessment of 5 Methods (Methylation\u2010Specific Polymerase Chain Reaction, MethyLight, Pyrosequencing, Methylation\u2010Sensitive High\u2010Resolution Melting, and Immunohistochemistry) to Analyze O6\u2010Methylguanine\u2010DNA\u2010Methyltranferase in a Series of 100 Glioblastoma Patients","volume":"118","author":"Quillien V.","year":"2012","journal-title":"Cancer"},{"issue":"9","key":"e_1_2_13_13_1","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1111\/cas.15024","article-title":"Combining MGMT Promoter Pyrosequencing and Protein Expression to Optimize Prognosis Stratification in Glioblastoma","volume":"112","author":"Li M.","year":"2021","journal-title":"Cancer Science"},{"key":"e_1_2_13_14_1","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-026-03092-2","article-title":"Performance of Propensity Score Methods in Observational Studies: A Systematic Review","volume":"15","author":"Tatari M.","year":"2026","journal-title":"Systematic Reviews"},{"issue":"6","key":"e_1_2_13_15_1","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/neuonc\/not027","article-title":"1p\/19q Codeletion and IDH1\/2 Mutation Identified a Subtype of Anaplastic Oligoastrocytomas With Prognosis as Favorable as Anaplastic Oligodendrogliomas","volume":"15","author":"Jiang H.","year":"2013","journal-title":"Neuro\u2010Oncology"},{"issue":"3","key":"e_1_2_13_16_1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11060-012-1026-x","article-title":"A New Prognostic Scoring Scale for Patients With Primary WHO Grade III Gliomas Based on Molecular Predictors","volume":"111","author":"Jiang H.","year":"2013","journal-title":"Journal of Neuro\u2010Oncology"},{"issue":"1","key":"e_1_2_13_17_1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11060-014-1526-y","article-title":"Polysomy of Chromosomes 1 and 19: An Underestimated Prognostic Factor in Oligodendroglial Tumors","volume":"120","author":"Jiang H.","year":"2014","journal-title":"Journal of Neuro\u2010Oncology"},{"key":"e_1_2_13_18_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.632547","article-title":"Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results From a Prospective Study","volume":"12","author":"Jiang H.","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"e_1_2_13_19_1","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/neuonc\/noaa225","article-title":"Association of Supratotal Resection With Progression\u2010Free Survival, Malignant Transformation, and Overall Survival in Lower\u2010Grade Gliomas","volume":"23","author":"Rossi M.","year":"2021","journal-title":"Neuro\u2010Oncology"},{"issue":"2","key":"e_1_2_13_20_1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3171\/2011.3.JNS101333","article-title":"Awake Surgery for WHO Grade II Gliomas Within \u201cNoneloquent\u201d Areas in the Left Dominant Hemisphere: Toward a \u201cSupratotal\u201d Resection. Clinical Article","volume":"115","author":"Yordanova Y. N.","year":"2011","journal-title":"Journal of Neurosurgery"},{"issue":"6","key":"e_1_2_13_21_1","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.3171\/2019.2.JNS183408","article-title":"Is Supratotal Resection Achievable in Low\u2010Grade Gliomas? Feasibility, Putative Factors, Safety, and Functional Outcome","volume":"132","author":"Rossi M.","year":"2020","journal-title":"Journal of Neurosurgery"},{"issue":"5","key":"e_1_2_13_22_1","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/neuonc\/noae264","article-title":"Neuro\u2010Oncological Superiority of Supratotal Resection in Lower\u2010Grade Gliomas","volume":"27","author":"Gallotti A. L.","year":"2025","journal-title":"Neuro\u2010Oncology"},{"issue":"1","key":"e_1_2_13_23_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25010612","article-title":"Pyrosequencing Analysis of O\u20106\u2010Methylguanine\u2010DNA Methyltransferase Methylation at Different Cut\u2010Offs of Positivity Associated With Treatment Response and Disease\u2010Specific Survival in Isocitrate Dehydrogenase\u2010Wildtype Grade 4 Glioblastoma","volume":"25","author":"Silva F.","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"e_1_2_13_24_1","doi-asserted-by":"crossref","DOI":"10.1093\/noajnl\/vdaf061","article-title":"Defining the Recommended Gray Zone in O6\u2010Methylguanine\u2010DNA Methyltransferase Promoter Methylation Pyrosequencing Reporting: A Robust, Translatable Method to Implement New EANO Guidelines","volume":"7","author":"Taylor P.","year":"2025","journal-title":"Neuro\u2010Oncology Advances"},{"issue":"10","key":"e_1_2_13_25_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102425","article-title":"Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild\u2010Type Glioblastoma Patients Treated With Radiochemotherapy: A Large Multicenter Study","volume":"14","author":"Caccese M.","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"e_1_2_13_26_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.23736\/S0390-5616.25.06421-5","article-title":"Optimal MGMT Promoter Methylation Cut\u2010Off to Predict Better Survival in Glioblastoma Patients Undergoing Gross\u2010Total Resection","volume":"70","author":"Fanizzi C.","year":"2026","journal-title":"Journal of Neurosurgical Sciences"},{"issue":"6","key":"e_1_2_13_27_1","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ijc.27385","article-title":"Predictive Impact of MGMT Promoter Methylation in Glioblastoma of the Elderly","volume":"131","author":"Reifenberger G.","year":"2012","journal-title":"International Journal of Cancer"},{"issue":"1","key":"e_1_2_13_28_1","doi-asserted-by":"crossref","first-page":"19758","DOI":"10.1038\/s41598-020-76312-x","article-title":"Extent and Prognostic Value of MGMT Promotor Methylation in Glioma WHO Grade II","volume":"10","author":"Karschnia P.","year":"2020","journal-title":"Scientific Reports"},{"issue":"1","key":"e_1_2_13_29_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00401-004-0861-z","article-title":"Population\u2010Based Study on Incidence, Survival Rates, and Genetic Alterations of Low\u2010Grade Diffuse Astrocytomas and Oligodendrogliomas","volume":"108","author":"Okamoto Y.","year":"2004","journal-title":"Acta Neuropathologica"},{"issue":"12","key":"e_1_2_13_30_1","doi-asserted-by":"crossref","first-page":"20354","DOI":"10.18632\/oncotarget.13555","article-title":"Impact of Epidemiological Characteristics of Supratentorial Gliomas in Adults Brought About by the 2016 World Health Organization Classification of Tumors of the Central Nervous System","volume":"8","author":"Jiang H.","year":"2017","journal-title":"Oncotarget"},{"issue":"18","key":"e_1_2_13_31_1","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1200\/JCO.2006.08.1661","article-title":"Prognostic Factors for Survival in Adult Patients With Recurrent Glioma Enrolled Onto the New Approaches to Brain Tumor Therapy CNS Consortium Phase I and II Clinical Trials","volume":"25","author":"Carson K. A.","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"e_1_2_13_32_1","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/neuonc\/noab105","article-title":"MGMT Promoter Methylation Testing to Predict Overall Survival in People With Glioblastoma Treated With Temozolomide: A Comprehensive Meta\u2010Analysis Based on a Cochrane Systematic Review","volume":"23","author":"Brandner S.","year":"2021","journal-title":"Neuro\u2010Oncology"},{"issue":"21","key":"e_1_2_13_33_1","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1158\/1078-0432.CCR-23-1295","article-title":"MGMT Promoter Methylation Predicts Overall Survival After Chemotherapy for 1p\/19q\u2010Codeleted Gliomas","volume":"29","author":"Kinslow C. J.","year":"2023","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"e_1_2_13_34_1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1001\/jamaoncol.2023.0990","article-title":"Association of MGMT Promoter Methylation With Survival in Low\u2010Grade and Anaplastic Gliomas After Alkylating Chemotherapy","volume":"9","author":"Kinslow C. J.","year":"2023","journal-title":"JAMA Oncology"},{"issue":"1","key":"e_1_2_13_35_1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/jcp.25896","article-title":"The Prognostic Value of MGMT Promoter Methylation in Glioblastoma: A Meta\u2010Analysis of Clinical Trials","volume":"233","author":"Binabaj M. M.","year":"2018","journal-title":"Journal of Cellular Physiology"},{"issue":"5","key":"e_1_2_13_36_1","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ccr.2010.03.017","article-title":"Identification of a CpG Island Methylator Phenotype That Defines a Distinct Subgroup of Glioma","volume":"17","author":"Noushmehr H.","year":"2010","journal-title":"Cancer Cell"},{"issue":"7390","key":"e_1_2_13_37_1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nature10866","article-title":"IDH1 Mutation Is Sufficient to Establish the Glioma Hypermethylator Phenotype","volume":"483","author":"Turcan S.","year":"2012","journal-title":"Nature"},{"issue":"3","key":"e_1_2_13_38_1","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","article-title":"Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma","volume":"164","author":"Ceccarelli M.","year":"2016","journal-title":"Cell"},{"issue":"2","key":"e_1_2_13_39_1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nrc3185","article-title":"Balancing Repair and Tolerance of DNA Damage Caused by Alkylating Agents","volume":"12","author":"Fu D.","year":"2012","journal-title":"Nature Reviews. Cancer"},{"key":"e_1_2_13_40_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mrrev.2017.10.001","article-title":"Epigenetic Regulation of DNA Repair Genes and Implications for Tumor Therapy","volume":"780","author":"Christmann M.","year":"2019","journal-title":"Mutation Research, Reviews in Mutation Research"},{"issue":"8","key":"e_1_2_13_41_1","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1158\/0008-5472.CAN-06-0127","article-title":"A Hypermutation Phenotype and Somatic MSH6 Mutations in Recurrent Human Malignant Gliomas After Alkylator Chemotherapy","volume":"66","author":"Hunter C.","year":"2006","journal-title":"Cancer Research"},{"issue":"2","key":"e_1_2_13_42_1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ccell.2018.04.011","article-title":"Biological Role and Therapeutic Potential of IDH Mutations in Cancer","volume":"34","author":"Waitkus M. S.","year":"2018","journal-title":"Cancer Cell"},{"issue":"10","key":"e_1_2_13_43_1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The Implications of IDH Mutations for Cancer Development and Therapy","volume":"18","author":"Pirozzi C. J.","year":"2021","journal-title":"Nature Reviews. Clinical Oncology"}],"container-title":["Annals of Clinical and Translational Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.70528","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acn3.70528","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.70528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:29:50Z","timestamp":1788931790000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acn3.70528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":42,"alternative-id":["10.1002\/acn3.70528"],"URL":"https:\/\/doi.org\/10.1002\/acn3.70528","archive":["Portico"],"relation":{},"ISSN":["2328-9503","2328-9503"],"issn-type":[{"value":"2328-9503","type":"print"},{"value":"2328-9503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"2026-05-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"acn3.70528"}}